Core Insights - Jyong Biotech Ltd. has successfully completed a Phase II clinical trial for its lead candidate, MCS-8, demonstrating significant efficacy in prostate cancer prevention and potential metabolic benefits [2][3][4] Clinical Efficacy - The Phase II trial involved over 700 high-risk subjects and showed a statistically significant 27.3% reduction in overall prostate cancer incidence in the MCS-8 group compared to placebo [3] - There was a 17.1% reduction in high-grade prostate cancer incidence, which is critical as high-grade malignancies are the main cause of prostate cancer mortality [3] - Further analysis indicated a 35.2% reduction in positive biopsy cores and a 24.4% reduction in cancer-positive areas within those cores, suggesting MCS-8's effectiveness in reducing tumor burden [4] Metabolic Benefits - Patients treated with MCS-8 exhibited a statistically significant reduction in total cholesterol (P = 0.036) and improvements in lipid profiles, including decreased triglycerides (P = 0.05) and LDL levels (P = 0.018), along with increased HDL (P = 0.003) [4] - In contrast, the placebo group showed a significant rise in fasting glucose (P = 0.022), indicating MCS-8's potential in addressing metabolic dysregulation associated with prostate cancer [4] Safety Profile - The Phase II study indicated a favorable safety profile for MCS-8, with no serious adverse events reported and no negative impacts on blood pressure, liver, or kidney function over two years [5] - Analysis of Lactate Dehydrogenase (LDH) levels showed no significant increase in the MCS-8 group, suggesting cytoprotection and a lack of cellular toxicity [6] Commercialization Strategy - Jyong Biotech has initiated strategic partnerships in Asia, including a non-binding Letter of Intent with a South Korean pharmaceutical company for the in-licensing of MCS-2, aimed at navigating regulatory landscapes [7] - A Memorandum of Understanding has also been established with a pharmaceutical distributor in Vietnam to explore the regulatory and commercial pathway for MCS-2, targeting a market with increasing demand for urological therapeutics [8] Management Perspective - The Chairwoman and CEO of Jyong Biotech emphasized the transformation of the company into one with clinically validated assets, highlighting the dual benefits of MCS-8 in reducing cancer incidence and improving metabolic health [9]

Core Insights - Jyong Biotech Ltd. announced updated statistical analyses from its Phase II clinical trial of MCS-8, highlighting its potential in treating urinary system diseases and possibly expanding to lipid management and cardiovascular diseases [1][3]. Clinical Trial Results - The Phase II clinical trial showed a 27.3% reduction in overall prostate cancer incidence and a 17.1% reduction in high-grade prostate cancer incidence compared to placebo [3]. - Long-term administration of MCS-8 for two years did not increase adverse events, with no serious adverse events or negative effects on liver, kidney function, or blood pressure observed [3]. Metabolic Indicators - MCS-8 demonstrated improved lipid control, with a statistically significant reduction in total cholesterol levels (P = 0.036) and no increase in serum lactate dehydrogenase (LDH) levels in the MCS-8 group, suggesting no cellular damage [2][7]. Development and Technology - MCS-8 is developed using Jyong Biotech's patented pharmaceutical composition technology, which enhances bioavailability and physiological efficacy, allowing for multiple dosage forms and indications [4]. Company Overview - Jyong Biotech Ltd. is a biotechnology company focused on developing innovative plant-derived drugs for urinary system diseases, with a commitment to research and development since its inception in 2002 [6].

Company Overview - Intelligent Bio Solutions Inc. (NASDAQ:INBS) announced plans to raise $10 million through a private placement, leading to a significant drop in its share price [1] - Following the announcement, shares of Intelligent Bio fell 19.7% to $7.65 [1] Stock Movements - Lavoro Limited (NASDAQ:LVRO) saw a substantial increase of 181%, reaching $1.2900 [4] - Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) rose 57.7% to $5.32 after issuing FY26 guidance, expecting US net sales of Linzess to be between $1.125 billion and $1.175 billion [4] - Brand Engagement Network, Inc. (NASDAQ:BNAI) jumped 56% to $3.6290 after entering a Vendor Services Project Agreement with a global advertising agency [4] - ChowChow Cloud International Holdings Limited (NYSE:CHOW) increased by 39.7% to $0.8500 due to year-over-year revenue and net income growth in H1 2025 [4] - Sidus Space, Inc. (NASDAQ:SIDU) gained 29% to $4.0314, marking a 470% surge over the past month [4] - Baidu, Inc. (NASDAQ:BIDU) rose 12.1% to $146.57 after announcing a proposed spin-off and Hong Kong listing of its AI unit [4] Declines - Outlook Therapeutics, Inc. (NASDAQ:OTLK) experienced a significant decline of 58% to $0.6632 after receiving a complete response letter from the FDA regarding its biologics license application [4] - ESH Acquisition Corp. (NASDAQ:ESHA) fell 23.5% to $14.68 [4] - Nuvve Holding Corp. (NASDAQ:NVVE) declined 15.3% to $2.1500 after announcing the closing of a private placement [4]

Group 1 - The article reports significant declines in the stock prices of several Chinese concept stocks, with notable drops including Wokai Medical down 32.92% and BitVentures down 21.57% [1] - The closing prices and trading volumes for the affected stocks are detailed, highlighting Wokai Medical's latest price at 0.0328 with a trading volume of 2.8645 million, and BitVentures at 1.200 with a trading volume of 0.5128 million [1] - Other companies experiencing declines include Dongfang Culture down 13.57%, Tongcheng Tongmei down 13.48%, and Jian Yong Biotechnology down 11.44%, indicating a broader trend of negative performance among these stocks [1]

Group 1 - U.S. stock futures were mostly flat, with Nasdaq 100 futures slipping around 0.01% [1] - Sidus Space, Inc. announced a public offering of 19,230,800 shares at $1.30 per share, leading to a 39.2% decline in its shares to $1.39 in pre-market trading [1] Group 2 - Starfighters Space Inc shares dipped 23.2% to $24.19 after a significant gain of over 370% on Monday [2] - ECD Automotive Design, Inc. fell 15.4% to $0.1650 following a 1-for-5 reverse stock split announcement [2] - CapsoVision Inc dipped 5.6% to $12.35, while Rocket Lab Corp fell 5.3% to $73.46 after a previous 10% jump [2] - Intuitive Machines Inc declined 5.2% to $15.82 despite a price target increase from $14 to $20 by B. Riley Securities [2] - Firefly Aerospace Inc shares declined 4.4% to $27.33 after a 16% increase due to joining the Russell 2000 and Russell 3000 indexes [2] - AST SpaceMobile Inc shares declined 3.1% to $83.82 after a 14% surge related to new satellite details [2]

Group 1 - The core point of the article highlights significant stock price increases for several Chinese concept stocks, with notable gains in their respective closing prices [1] Group 2 - Haoxin Holdings (HXHX) experienced a remarkable increase of 273.91%, closing at 1.2900, with a trading volume of 270 million [1] - Meihua Chuangfu (MGRT) saw a rise of 70.41%, closing at 12.440, with a trading volume of 4.6887 million [1] - Jian Yong Biotechnology (MENS) increased by 50.55%, closing at 4.780, with a trading volume of 124 million [1] - Zhongchi Chefu (AZI) rose by 32.80%, closing at 3.320, with a trading volume of 163 million [1] - Paiming Xincheng (IZM) gained 28.00%, closing at 1.600, with a trading volume of 1.2584 million [1]

Market Overview - U.S. stocks experienced an upward trend, with the Nasdaq Composite increasing by over 100 points on Monday. The Dow rose by 0.18% to 48,222.17, the NASDAQ increased by 0.56% to 23,439.24, and the S&P 500 gained 0.45% to 6,864.96 [1] - Asian markets closed higher, with Japan's Nikkei 225 gaining 1.81%, Hong Kong's Hang Seng up 0.43%, China's Shanghai Composite rising 0.69%, and India's BSE Sensex increasing by 0.75% [6] Sector Performance - Energy shares rose by 1.3% on Monday, while utilities stocks fell by 0.5% [1] Commodity Prices - Oil prices increased by 2.2% to $57.75, gold rose by 1.7% to $4,463.30, silver was up 2.5% to $69.150, and copper fell by 0.1% to $5.5085 [4] European Market Performance - European shares were lower, with the eurozone's STOXX 600 declining by 0.3%, Spain's IBEX 35 Index falling by 0.2%, London's FTSE 100 down by 0.5%, Germany's DAX 40 decreasing by 0.3%, and France's CAC 40 dropping by 0.5% [5] Notable Stock Movements - Haoxin Holdings Limited (NASDAQ:HXHX) shares surged by 118% to $0.7513, while Sidus Space, Inc. (NASDAQ:SIDU) increased by 78% to $2.0650 after receiving a contract from the Missile Defense Agency [8] - Jyong Biotech Ltd. (NASDAQ:MENS) shares rose by 36% to $4.32 [8] - Luminar Technologies, Inc. (NASDAQ:LAZR) shares dropped by 60% to $0.2396 after announcing voluntary Chapter 11 proceedings [8] - EUDA Health Holdings Limited (NASDAQ:EUDA) shares fell by 25% to $2.09 following a strategic technology integration announcement [8] - Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) shares decreased by 20% to $1.74 as the company announced a self tender offer [8]

Core Viewpoint - Jyong Biotech Ltd. is experiencing fluctuations in its share price and increased trading volume following the expiry of the lock-up period, while engaging with investment funds interested in purchasing its shares [1]. Company Overview - Jyong Biotech Ltd. is a biotechnology company based in Taiwan, focused on developing and commercializing innovative plant-derived drugs, particularly for urinary system diseases, with a target market in the U.S., EU, and Asia [6]. - The company has established integrated capabilities across all key functionalities of drug development since its inception in 2002, including drug discovery, clinical trials, and commercialization [6]. Financial and Operational Status - The company's research and development operations remain solid, and its financial condition is consistent with recent public filings, including the Current Report on Form 6-K [3]. - Jyong Biotech has completed four Phase III clinical trials in the U.S. and Taiwan, along with one Phase II clinical trial in Taiwan, and is advancing its investigational pipeline [5]. Strategic Developments - The company holds global multi-country invention patents, providing market protection across the Americas, Asia, and Europe, and has signed Letters of Intent (LOIs) with several international pharmaceutical companies [5]. - Jyong Biotech is committed to expanding its global presence and aims to deliver world-class botanical new drugs to address significant unmet medical needs [5]. Compliance and Disclosure - The company confirms compliance with SEC regulations and is not aware of any material, unpublished price-sensitive information that would explain the recent trading activity [2][4].

Group 1 - The core point of the article highlights significant declines in the stock prices of several Chinese concept stocks, with notable drops including Jian Yong Biotechnology down 81.04% and Antelope Holdings down 25.73% [1] Group 2 - Jian Yong Biotechnology (MENS) closed at 2.920, experiencing a drop of 81.04%, which translates to a decrease of 12.480, with a trading volume of 13.1486 million [1] - Antelope Holdings (AEHL) closed at 1.790, down 25.73%, reflecting a decline of 0.620, with a trading volume of 0.4457 million [1] - 3 E Network Technology (MASK) saw a decrease of 22.96%, closing at 0.2620, down 0.0781, with a trading volume of 0.7766 million [1] - Token Cat (TC) closed at 12.000, down 21.77%, which is a drop of 3.340, with a trading volume of 1.0489 million [1] - Everbright Digital (EDHL) closed at 0.4515, down 17.49%, reflecting a decrease of 0.0957, with a trading volume of 0.2571 million [1]

Group 1 - The core point of the article highlights significant declines in the stock prices of several Chinese concept stocks, with CIMG experiencing the largest drop of 31.98% [1] - CIMG's latest price is reported at 1.170, with a decrease of 0.550 and a trading volume of 1.7132 million [1] - Other notable declines include MENS down 31.22% to 15.400, CGTL down 18.63% to 0.952, NCRA down 18.60% to 1.050, and MASK down 17.05% to 0.3401 [1][1][1] Group 2 - The trading volume for MENS was 6.5639 million, while CGTL had a trading volume of 1.1541 million [1] - NCRA's trading volume was 0.4163 million, and MASK's trading volume was 1.8397 million [1][1]